Bendamustine–rituximab elicits dual tumoricidal and immunomodulatory responses via cGAS–STING activation in diffuse large B-cell lymphoma
This unique dual influence not only directly targets DLBCL cells but also engages the patient's immune system, paving the way for innovative combination therapies. The study provides comprehensive insights into the multifaceted actions of BR in DLBCL, offering a foundation for refined and personalized treatment strategies in elderly patients.
Authors
- Enguang Bi (ORCID: https://orcid.org/0000-0003-0850-8135)
- Yang Zhou (ORCID: https://orcid.org/0000-0001-8630-3464)
- Ruipei Xiao (ORCID: https://orcid.org/0009-0009-6998-3651)
- Ling Jiang (ORCID: https://orcid.org/0000-0003-1464-5881)
- Yi Xiao (ORCID: https://orcid.org/0000-0001-7274-6774)
- Wei Meng
- Wenli Zhao
- Wei Lin (ORCID: https://orcid.org/0000-0002-0455-8752)
- Jie Ren (ORCID: https://orcid.org/0000-0002-6450-3163)
Institutions
- Nanfang Hospital (CN)
- Zhujiang Hospital (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1136/jitc-2024-009212
- Citations
- 10
- Primary Topic
- interferon and immune responses
- Type
- article
- Field-Weighted Citation Impact
- 2.40
Funders
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province